. 2022 Jul 22;39(10):e14913. doi: 10.1111/dme.14913

TABLE 3.

Exclusion criteria of three type 1 diabetes prevention trials testing incretin‐based therapy in islet autoantibody positive participants

Exclusion criteria (trial specific)
Stage 1 trial	Stage 2 trial	Stage 3 trial
Type 1 diabetes	Type 1 diabetes
Dysglycaemia ^a

Exclusion criteria (common):
Allergy to liraglutide or other ingredients of Victoza® Ketoacidosis Previous treatment in the last 3 months with any antidiabetic medication Impaired liver or kidney function or on dialysis Severe heart failure Severe gastrointestinal problem resulting in gastroparesis, or IBD Past or current history of pancreatitis Serum calcitonin value above normal (>50 ng/L or ≥3.4 pmoL/L) Presence or history of any significant metabolic, hematologic or malignant disease Pregnant female participants and female participants of child‐bearing potential using inadequate contraception Breastfeeding

Exclusion criteria (common):

Allergy to liraglutide or other ingredients of Victoza®

Ketoacidosis

Previous treatment in the last 3 months with any antidiabetic medication

Impaired liver or kidney function or on dialysis

Severe heart failure

Severe gastrointestinal problem resulting in gastroparesis, or IBD

Past or current history of pancreatitis

Serum calcitonin value above normal (>50 ng/L or ≥3.4 pmoL/L)

Presence or history of any significant metabolic, hematologic or malignant disease

Pregnant female participants and female participants of child‐bearing potential using inadequate contraception

Breastfeeding

Defined as having IFG (impaired fasting glucose) or IGT (impaired glucose tolerance), or 10% rise in haemoglobin A1c (HbA1c) or HbA1c ≥5.9% (41 mmol/mol) measured within the last 12 months, or plasma glucose ≥11.1 mmoL/L at 30, 60, or 90 min timepoints during oral glucose tolerance test. IBD, inflammatory bowel disease.